Catalyst Pharma announces $200M share repurchase program through Dec 2026

CATALYST PHARMACEUTICALS, INC.

Board authorized up to $200M share repurchase from Oct 1, 2025 to Dec 31, 2026.
Company had >$650M cash & equivalents and no funded debt as of June 30, 2025.
Repurchases may be via open market or privately negotiated; timing depends on stock price and conditions.
Program may be suspended or terminated anytime; no obligation to buy any specific amount.
Company plans to use existing cash on hand to fund the repurchase program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.